[HTML][HTML] Event-free survival with pembrolizumab in early triple-negative breast cancer
…, M Ferreira, MA Mouret-Reynier… - … England Journal of …, 2022 - Mass Medical Soc
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
significantly higher percentage of patients with early triple-negative breast cancer having a …
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
…, X Durando, MA Mouret-Reynier… - Critical reviews in …, 2015 - Elsevier
Breast cancer is heterogeneous in clinical, morphological, immunohistochemical and
biological features, as reflected by several different prognostic subgroups. Neoadjuvant …
biological features, as reflected by several different prognostic subgroups. Neoadjuvant …
[HTML][HTML] Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor …
…, AJ Montero, F Forget, MA Mouret-Reynier… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA …
…, L Christelle, MA MOURET-REYNIER… - The Lancet …, 2022 - thelancet.com
Background In advanced oestrogen receptor-positive, HER2-negative breast cancer,
acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones …
acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones …
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
…, E Planchat, C Abrial, MA Mouret-Reynier… - Cancer biology & …, 2010 - Taylor & Francis
Background. Since the improvement of chemotherapy with safe molecules is needed for
better efficacy without supplementary toxicity, we investigated the feasibility and tolerability …
better efficacy without supplementary toxicity, we investigated the feasibility and tolerability …
Incorporation of pazopanib in maintenance therapy of ovarian cancer
…, KH Baumann, MA Mouret-Reynier… - Journal of clinical …, 2014 - ascopubs.org
Purpose Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR …
…, W Janni, R O'Regan, MA Mouret-Reynier… - The Lancet …, 2018 - thelancet.com
Background Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …
[HTML][HTML] Mutational profile of metastatic breast cancers: a retrospective analysis
…, G Romieu, L Vanlemmens, MA Mouret Reynier… - PLoS …, 2016 - journals.plos.org
Background Major advances have been achieved in the characterization of early breast
cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor …
cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor …
[HTML][HTML] Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
…, G Le Bouedec, MA Mouret-Reynier… - British journal of …, 2002 - nature.com
Only a few papers have been published concerning the incidence and outcome of patients
with a pathological complete response after cytotoxic treatment in breast cancer. The …
with a pathological complete response after cytotoxic treatment in breast cancer. The …
[HTML][HTML] Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
…, M Debled, W Jacot, MA Mouret-Reynier… - European journal of …, 2018 - Elsevier
Aim Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC)
patients may help define medical needs and evaluate the impact of public health …
patients may help define medical needs and evaluate the impact of public health …